{Reference Type}: Systematic Review
{Title}: Radiotherapy of orbital metastases: a systematic review of management and treatment outcomes on behalf of palliative care study group of Italian association of radiotherapy and clinical oncology (AIRO).
{Author}: Pezzulla D;Di Franco R;Zamagni A;Pastore F;Longo S;Dominici L;Lillo S;Ciabattoni A;Arcidiacono F;Deodato F;Muto P;Morganti AG;Cellini F;Maranzano E;
{Journal}: Br J Radiol
{Volume}: 96
{Issue}: 1151
{Year}: 2023 Nov 11
{Factor}: 3.629
{DOI}: 10.1259/bjr.20230124
{Abstract}: <B>UNASSIGNED: </B>We search the current literature on data regarding the role of RT in OM treatment, focusing on the improvement of symptoms and patient quality of life.<BR><B>UNASSIGNED: </B>This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations.<BR><B>UNASSIGNED: </B>From 340 citations, 60 papers were finally selected: 45 case reports and 15 case series. The case reports accounted for 47 patients. In 37/39 cases (95%), EBRT was done. Patients were mainly treated with 3DCRT, IMRT, and with SBRT. The most used RT regimens were 30 Gy in 10 fractions (23%) and 20-25 Gy in 5 fx (13%). No sever toxicity was reported. A median LC of 11 months (range 1-54 months) and a median OS of 12 months (range 1-54 months) were registered. Among the case series, a total of 457 patients were examined, 227 of whom underwent RT. The main used techniques were 3DCRT, CK, GK, SBRT, and BRT. RT doses could vary from 30 Gy/10 fractions to 60 Gy/30 fractions, 50 Gy/5 fractions, or 16.5-21 Gy in single fraction. No toxicity above G2 was reported. ORR could vary between 75 and 100%. Only two study provided information on response duration: a mean LC time of 22.8 months and a mean time to local progression of 5 months (range: 3-7). Regarding OS, the data were heterogeneous, ranging between 1 and 54 months.<BR><B>UNASSIGNED: </B>RT for OM seems to be a safe and feasible option. More information on the RT ideal techniques and dose are still needed.<BR><B>UNASSIGNED: </B>This paper tried to sum up the few and fragmented data on the use of radiotherapy for orbital metastases: the possible option ranged from 3D- and 2D-CRT to SBRT, CK, and GK, with different possible fractionations (30Gy in 10 fractions, 60 Gy/30 fractions, 20-50 Gy/5 fractions, or 16.5-21 Gy in single fraction). Regardless of the chosen approach, almost all treated patients experienced a benefit after RT in terms of OM-related symptom intensity reduction and a good acute and late toxicity profile.